In research literature, GHK-Cu is generally treated as a copper(II)-binding tripeptide (Gly-His-Lys) that forms a stable 1:1 complex with Cu²⁺ and is studied in extracellular matrix gene-expression and wound-signalling assay models. GHK binds Cu²⁺ with extraordinary affinity (Kd ≈ 10⁻¹⁵ M) via coordination through the glycine α-amino group, histidine imidazole Nδ, and the lysine α-amino group — a square-planar complex that remains intact under physiological conditions. The copper-loaded form (GHK-Cu) has been studied for upregulation of collagen I, collagen III, fibronectin, and the proteoglycan decorin in fibroblast assay models, with mechanistic proposals centring on TGF-β pathway modulation and activation of metalloenzymes. Gene-expression profiling studies report broad transcriptional changes across matrix-remodelling, antioxidant defence, and neurotrophin-related gene sets, making it a tool for wide-scope transcriptomic research in addition to targeted pathway assays.
The copper complex changes the optical and electrochemical properties of the peptide relative to the metal-free form, which makes analytical characterisation methods (UV-Vis, circular dichroism, ICP-MS for copper quantification) relevant workflow steps before cell-based experiments. Comparative studies between GHK and GHK-Cu allow researchers to attribute transcriptional or matrix effects specifically to copper coordination versus the bare tripeptide scaffold. For laboratory teams, the practical emphasis is usually on sequence identity, receptor or pathway relevance where documented, and whether GHK-Cu behaves consistently across stability, purity, and analytical verification workflows. Variant labels on this page support clearer internal referencing when multiple labelled variants are under review.